Preemptive sequencing in the genomic medicine era

Charu Kaiwar, Tammy M. McAllister, Konstantinos N Lazaridis, Eric W Klee

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: As genomic medicine finds its way into clinical practice, preemptive sequencing is being applied in various aspects of health care. In this review we take stock of the implications of this preemptive collection of information and how the current health care system is evolving to accommodate the privilege of this vast, permanent and deeply private knowledge about our individual selves. Areas covered: In this review we have explored the current standing of preemptive sequencing in regards to return of results for the ACMG 59, pharmacogenomics, prenatal screening, and direct to consumer genetic testing. We attempt to point to the advancements in academics and bioinformatics that it has triggered as well as highlight the various questions that have emerged as a result. Expert commentary: In the first two decades since the genome was sequenced, we have realized that our current health care system needs to go a long way until we can truly leverage our ability to read our genomes to personalize our medical needs. High throughput genomic sequencing is a first step toward more proactive or preemptive practice rather than the thus far reactive practice of medicine.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalExpert Review of Precision Medicine and Drug Development
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Medicine
Delivery of Health Care
Genome
Genetic Testing
Computational Biology
Prenatal Diagnosis
Pharmacogenomic Testing
Direct-To-Consumer Screening and Testing

Keywords

  • ACMG 59
  • Direct-to-consumer testing
  • Pharmacogenomics
  • Preemptive sequencing
  • Prenatal screening

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Preemptive sequencing in the genomic medicine era. / Kaiwar, Charu; McAllister, Tammy M.; Lazaridis, Konstantinos N; Klee, Eric W.

In: Expert Review of Precision Medicine and Drug Development, Vol. 2, No. 2, 01.01.2017, p. 91-98.

Research output: Contribution to journalReview article

@article{ec0d259ae0674ae3a0ec02eac3a7a52d,
title = "Preemptive sequencing in the genomic medicine era",
abstract = "Introduction: As genomic medicine finds its way into clinical practice, preemptive sequencing is being applied in various aspects of health care. In this review we take stock of the implications of this preemptive collection of information and how the current health care system is evolving to accommodate the privilege of this vast, permanent and deeply private knowledge about our individual selves. Areas covered: In this review we have explored the current standing of preemptive sequencing in regards to return of results for the ACMG 59, pharmacogenomics, prenatal screening, and direct to consumer genetic testing. We attempt to point to the advancements in academics and bioinformatics that it has triggered as well as highlight the various questions that have emerged as a result. Expert commentary: In the first two decades since the genome was sequenced, we have realized that our current health care system needs to go a long way until we can truly leverage our ability to read our genomes to personalize our medical needs. High throughput genomic sequencing is a first step toward more proactive or preemptive practice rather than the thus far reactive practice of medicine.",
keywords = "ACMG 59, Direct-to-consumer testing, Pharmacogenomics, Preemptive sequencing, Prenatal screening",
author = "Charu Kaiwar and McAllister, {Tammy M.} and Lazaridis, {Konstantinos N} and Klee, {Eric W}",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/23808993.2017.1322898",
language = "English (US)",
volume = "2",
pages = "91--98",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Preemptive sequencing in the genomic medicine era

AU - Kaiwar, Charu

AU - McAllister, Tammy M.

AU - Lazaridis, Konstantinos N

AU - Klee, Eric W

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: As genomic medicine finds its way into clinical practice, preemptive sequencing is being applied in various aspects of health care. In this review we take stock of the implications of this preemptive collection of information and how the current health care system is evolving to accommodate the privilege of this vast, permanent and deeply private knowledge about our individual selves. Areas covered: In this review we have explored the current standing of preemptive sequencing in regards to return of results for the ACMG 59, pharmacogenomics, prenatal screening, and direct to consumer genetic testing. We attempt to point to the advancements in academics and bioinformatics that it has triggered as well as highlight the various questions that have emerged as a result. Expert commentary: In the first two decades since the genome was sequenced, we have realized that our current health care system needs to go a long way until we can truly leverage our ability to read our genomes to personalize our medical needs. High throughput genomic sequencing is a first step toward more proactive or preemptive practice rather than the thus far reactive practice of medicine.

AB - Introduction: As genomic medicine finds its way into clinical practice, preemptive sequencing is being applied in various aspects of health care. In this review we take stock of the implications of this preemptive collection of information and how the current health care system is evolving to accommodate the privilege of this vast, permanent and deeply private knowledge about our individual selves. Areas covered: In this review we have explored the current standing of preemptive sequencing in regards to return of results for the ACMG 59, pharmacogenomics, prenatal screening, and direct to consumer genetic testing. We attempt to point to the advancements in academics and bioinformatics that it has triggered as well as highlight the various questions that have emerged as a result. Expert commentary: In the first two decades since the genome was sequenced, we have realized that our current health care system needs to go a long way until we can truly leverage our ability to read our genomes to personalize our medical needs. High throughput genomic sequencing is a first step toward more proactive or preemptive practice rather than the thus far reactive practice of medicine.

KW - ACMG 59

KW - Direct-to-consumer testing

KW - Pharmacogenomics

KW - Preemptive sequencing

KW - Prenatal screening

UR - http://www.scopus.com/inward/record.url?scp=85054744145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054744145&partnerID=8YFLogxK

U2 - 10.1080/23808993.2017.1322898

DO - 10.1080/23808993.2017.1322898

M3 - Review article

VL - 2

SP - 91

EP - 98

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 2

ER -